

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT  
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **June 12, 2017**

**INDIA GLOBALIZATION CAPITAL, INC.**

(Exact name of registrant as specified in its charter)

**Maryland**  
(State or other jurisdiction of incorporation)

**001-32830**  
(Commission File Number)

**20-2760393**  
(I.R.S. Employer Identification No.)

**4336 Montgomery Ave., Bethesda, Maryland 20814**  
(Address of principal executive offices) (Zip Code)

**(301) 983-0998**  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1934 (§240.12b-2 of this chapter) Emerging growth company .

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**Item 8.01 Other Events.**

India Globalization Capital, Inc. (the “Company”) (NYSE MKT: IGC), has distributed a press release to announce that it has entered into a definitive license agreement with the University of South Florida making IGC the exclusive licensee of the U.S. patent filing entitled “THC as a Potential Therapeutic Agent for Alzheimer’s Disease.”

A copy of the press release is filed as Exhibit 99.1 to this Form 8-K and is incorporated by reference into this Item 8.01 in its entirety.

**Cautionary Statement Pursuant to Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995:**

“Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This report contains forward-looking statements identified by the use of words such as should, believes, plans, goals, expects, may, will, or the negatives thereof, and other variations thereon or comparable terminology. Such statements are based on currently available information, which management has assessed but which is dynamic and subject to rapid change due to risks and uncertainties that affect our business. **Our success is highly correlated with the success of our product candidates. We may not be able to protect our intellectual property adequately, or receive patents. We may not receive regulatory approval for our products, or trials. An additional risk factor worth highlighting specifically related to this patent licensing is that the patent application we have licensed may not be granted by the USPTO. We may not have adequate resources including financial resources to successfully conduct the requisite trials. We may not be able to successfully commercialize our products even if they are successful and receive regulatory approval. Our projections anticipate stable pricing, which may not hold out over the next several years. Failure or delay with respect to any of the factors above could have a material adverse effect on our business, future results of operations, our stock price, and our financial condition.** These and other risks are detailed from time to time in our filings with the U.S. Securities and Exchange Commission. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be forward-looking statements. Forward-looking statements involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

The exhibit listed in the following Exhibit Index is filed as part of this current report.

<u>Exhibit Number</u>	<u>Exhibit Description</u>
-----------------------	----------------------------

99.1	<a href="#">Press release “IGC Acquires Exclusive Rights to THC-based treatment for Alzheimer’s Disease,” dated June 12, 2017.</a>
------	--

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**India Globalization Capital, Inc.**

Date: June 12, 2017

By: /s/ John Cherin  
John Cherin  
Chief Financial Officer, Treasurer,  
and Principal Accounting Officer

---

**Exhibit Index**

- 99.1 [Press release “IGC Acquires Exclusive Rights to THC-based treatment for Alzheimer’s Disease.” dated June 12, 2017.](#)

## Exhibit 99.1

### IGC Acquires Exclusive Rights to THC-based treatment for Alzheimer's Disease

Bethesda, June 12, 2017 - India Globalization Capital, Inc. (NYSE-MKT: IGC) is pleased to announce that it has entered into a definitive license agreement with the University of South Florida making IGC the exclusive licensee of the U.S. patent filing entitled "THC as a Potential Therapeutic Agent for Alzheimer's Disease." **By acquiring this patent filing, IGC is protecting a potential cannabis-based blockbuster treatment for America's most expensive disease.**

#### Alzheimer's Disease Market Overview

In 2017 Medicare and Medicaid alone are expected to spend **\$175 billion** on patients diagnosed with Alzheimer's. There are currently over 5.3 million Americans with Alzheimer's (AD). The cost of Alzheimer's has increased significantly and is expected to continue to surge higher. The number of patients is expected to double over the next 20 years and the direct costs are expected to exceed **\$450 billion per year** in the next 12 years. There is still no accepted cure for Alzheimer's Disease.

#### The Patent

THC has several known molecular pathways by which it interacts with the human body, including binding to the CB1 receptor, anti-oxidative effects, and others. The patent filing claims discovery of a new pathway: low doses of THC bind to amyloid beta plaques and prevent those plaques from aggregating on neurons, which is what occurs in Alzheimer's disease and causes cognitive decline. **If the patent is granted and proven, IGC will own a significant therapeutic pathway by which THC interacts with the human body. The pathway has incredible potential in treating Alzheimer's disease and is now a burgeoning research area.** Acquiring this patent further supports IGC in protecting its **proprietary formulation IGC-AD1**, which includes low-doses of THC and is intended to disrupt the buildup of amyloid beta plaques and alleviate some of the worst symptoms of Alzheimer's disease.

#### Next Steps

"Securing this licensing agreement from the University of South Florida represents a major turning point for IGC as we now look to prepare several of our key products for clinical trials." explained Ram Mukunda, CEO of IGC. "We have worked hard to assemble a strong development team and a primary pipeline of four major products addressing large markets and possible blockbuster indications utilizing cannabis-based therapies. We are putting the finishing touches on our products, which may include filing additional patents, and **we very much expect to start pursuing clinical trials for our Alzheimer's product and others this year.**" IGC also expects in the near future to share some data that supports its formulation, the patent application, and the transition to clinical trials as well as details of commercialization initiatives.

#### About IGC

India Globalization Capital Inc. is engaged in the development of cannabis-based therapies to treat cachexia, nausea, vomiting, Parkinson's Disease, Alzheimer's Disease, epilepsy, PTSD and other life altering conditions in humans and animals. In support of this mission, IGC has assembled a portfolio of patent filings for its phytocannabinoid-based treatments. The company is based in Bethesda, Maryland.

For more information, visit [www.igcinc.us](http://www.igcinc.us)

Follow us on Twitter @IGCIR and Facebook.com/IGCIR/

#### Forward-looking Statements, Statistics, and Risk Factors

Please see cautionary statements related to Safe Harbor, forward-looking statements, and risk factors discussed in India Globalization Capital, Inc.'s Form 10-K for fiscal year ended March 31, 2016, and in subsequent reports, including the June 12, 2017 report on Form 8-K, filed with the U.S. Securities and Exchange Commission. Statistics on Alzheimer's Disease are cited from the website of the Alzheimer's Association ([alz.org](http://alz.org)).

#### Contact Info:

Claudia Grimaldi  
301-983-0998